KOSDAQRetail & Consumer065650

Hyper

₩1,317▲ 0.61%2026-11-18 close
Market Cap
₩14.4B
Turnover
₩19,581,926
Volume
20K
Shares out.
11M
PER
—
PBR
0.7×
EPS
-₩798
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Narrowing, but Financing and Dilution Risks Rising

Revenue has risen for three straight years through 2025, and operating losses narrowed sharply in the third quarter of 2026. Still, the rising debt ratio, operating cash outflows and convertible bond and rights offering disclosures remain key financial variables for Hyper.

  1. 1

    Revenue grew from KRW 45.3 billion in 2022 to KRW 76.2 billion in 2025, with 2025 up 30.3% year on year.

  2. 2

    Hyper has posted operating losses for four consecutive years from 2022 to 2025, and the KRW 4.28 billion loss in 2025 was smaller than the KRW 6.05 billion loss in 2024.

  3. 3

    The third-quarter 2026 operating loss narrowed to KRW 85.3 million from KRW 865 million a year earlier, but losses have continued for five consecutive quarters, and the last four quarters total KRW 9.03 billion in net loss attributable to controlling shareholders.

  4. 4

    The debt ratio stood at 369.8% at the end of 2025, with total liabilities of KRW 56.6 billion against total equity of KRW 15.3 billion, and operating cash flow was an outflow of KRW 8.29 billion.

  5. 5

    According to a Daily Yonhap report, cumulative convertible bond issuance decisions total KRW 70.5 billion, and rights offering decisions, corrections and withdrawals were repeated between June and November 2026, so execution will change the share count and capital structure.

02

Business structure

Hyper, founded in 1997, runs three business units: commerce, life care and tech. The commerce unit sells Logitech PC peripherals such as mice, keyboards, headsets and webcams through Coupang Rocket Delivery and Kakao Shopping, and has expanded into home appliances such as Ecovacs robot vacuums.

The same unit also provides digital marketing strategy consulting and advertising agency services.

The life care unit holds a set of bio pipelines, including an NLRP3 inhibitor-based anti-inflammatory drug, an Alzheimer's treatment, the non-opioid analgesic MDR-652 and the early dementia diagnostic kit QPLEX Alz Plus, which has MFDS product approval and is on sale.

The tech unit operates Xclusive, a blockchain-based Web 3.0 platform that handles creators' content ownership and viewing-right transactions.

At an extraordinary general meeting on March 12, 2026, shareholders approved articarticles of incorporation changes adding business purposes such as mobile voucher and coupon wholesale, advertising agency work, live commerce, MCN and OEM and ODM manufacturing, according to a Digital Today report.

Short-form drama production, a commerce-linked platform and wider global partnerships are listed as initiatives in an FnGuide business summary. Segment revenue shares are not disclosed in the filings used here, so they are not shown as figures.

Press coverage credited the high growth of the Logitech distribution business with strong results, which suggests commerce is the core of revenue. The revenue contribution of the bio unit is not confirmed by filings.

Competition in PC peripheral online distribution centers on platform listings, while home appliances compete with established appliance distributors.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩23.1B-₩900M−3.7%
2025Q4₩19.6B-₩1.2B−6.1%
2026Q1₩23.5B-₩500M−2.0%
2026Q2₩18.7B-₩2.5B−13.3%
2026Q3₩23.2B-₩85,301,205−0.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩45.3B-₩4.1B-₩12B−9.0%−38.7%79.3%
2023₩52B-₩1.3B-₩2B−2.6%−5.3%51.2%
2024₩58.5B-₩6.1B-₩80.4B−10.4%−459.5%245.4%
2025₩76.2B-₩4.3B-₩300M−5.6%−2.1%369.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

According to DART regular reports, annual revenue rose from KRW 45.3 billion in 2022 to KRW 52 billion in 2023 (up 14.9% year on year), KRW 58.5 billion in 2024 (up 12.3%) and KRW 76.2 billion in 2025 (up 30.3%).

Revenue has increased for three consecutive years from 2023 to 2025, and 2025 was the largest year in the 2022 to 2025 period.

Operating losses over the same span were KRW 4.06 billion in 2022, KRW 1.35 billion in 2023, KRW 6.05 billion in 2024 and KRW 4.28 billion in 2025, which means four consecutive years of operating losses. The loss narrowed in 2023, widened in 2024 and narrowed again in 2025.

The operating margin was -9.0% in 2022, -2.6% in 2023, -10.4% in 2024 and -5.6% in 2025, so profitability did not improve steadily even as sales grew. Net loss attributable to controlling shareholders was KRW 12 billion in 2022, KRW 1.96 billion in 2023, KRW 80.4 billion in 2024 and KRW 316 million in 2025.

The 2024 figure is far larger than that year's operating loss of KRW 6.05 billion, which points to a large non-operating impact. Net loss including non-controlling interests was KRW 81.2 billion in 2024 and KRW 756 million in 2025.

Operating cash flow was an outflow of KRW 2.91 billion in 2022, KRW 2.14 billion in 2023, KRW 4.54 billion in 2024 and KRW 8.29 billion in 2025, widening each year. The debt ratio rose from 51.2% in 2023 to 245.4% in 2024 and 369.8% in 2025.

Quarterly revenue was KRW 23.1 billion in the third quarter of 2025, KRW 19.6 billion in the fourth quarter (down 15.3% quarter on quarter), KRW 23.5 billion in the first quarter of 2026 (up 20.1%), KRW 18.7 billion in the second quarter (down 20.7%) and KRW 23.2 billion in the third quarter (up 24.4%, or up 0.4% year on year).

The operating loss was KRW 865 million, KRW 1.18 billion, KRW 472 million, KRW 2.49 billion and KRW 85.3 million across the same five quarters, so the third quarter of 2026 had the smallest loss of the period, while the second quarter had the largest.

Losses have continued for five consecutive quarters from the third quarter of 2025 to the third quarter of 2026, and the last four quarters total KRW 9.03 billion in net loss attributable to controlling shareholders.

Quarterly disclosures do not identify one-off items by line, so the annual breakdown should be checked in the 2026 annual report.

05

Industry analysis

Hyper is classified under the distribution and consumer goods sector, but its revenue mix combines PC peripheral distribution, home appliance distribution and a bio pipeline.

Online PC peripheral sales depend on large platform channels such as Coupang Rocket Delivery, so listing terms and platform policies affect the business. An FnGuide business summary attributes demand for home appliances such as robot vacuums partly to the growth of single-person households.

The scale and profitability of the home appliance expansion are not confirmed by filed figures. The bio unit targets Alzheimer's treatment and diagnostics, and the company is described as a clinical-stage biopharmaceutical business.

In this field, commercialization timing depends heavily on clinical results and approvals. Listed peers in the same sector include Coway, Cuckoo Homesys and Hanssem, all in home appliances or furniture. Compared with them, Hyper is much smaller by market capitalization and combines distribution with a bio pipeline. Confirmed sector demand indicators are limited.

06

Outlook

The direction of expansion first appeared in the March 2026 articles of incorporation changes, which added advertising agency work, live commerce, MCN and OEM and ODM manufacturing to the business purposes. This points to a move from distribution toward content and marketing.

Short-form drama production, a commerce-linked platform and wider global partnerships are also listed as initiatives. On the bio side, the company has said it has begun commercialization focused on new drugs and diagnostic devices, as reported by Edaily.

The QPLEX Alz Plus diagnostic kit is approved by the MFDS and on sale, but commercialization timing for the drug pipeline is not confirmed by filed figures.

On funding, a Daily Yonhap report says cumulative convertible bond issuance decisions total KRW 70.5 billion, equal to 386.8% of year-end cash, and the largest single-tranche potential dilution is 44.69%.

Rights offering decisions, corrections and withdrawals, along with extraordinary shareholder meeting notices and corrections, were repeated between June and November 2026.

A designation as an unfaithful disclosure company was flagged in March 2026 because the number and value of shares in a rights offering changed by 20% or more. The next checkpoints are whether the conversions and rights offerings are executed and how the share count changes.

07

Valuation

PER
—
PBR
0.7×
ROE
-37.3%
EPS
-₩798
BPS
₩2,119
Dividend per share
₩0

Because net losses attributable to controlling shareholders have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. Earnings-based multiples are therefore hard to compare, and the price relative to book net assets is the more commonly used reference.

The price-to-book ratio has been moving below 1x, which means the stock trades at a discount to net assets. However, year-end 2025 total equity of KRW 15.3 billion against total liabilities of KRW 56.6 billion shows that book net assets have been affected by rising debt and accumulated losses.

Dividends are effectively not paid, so the dividend yield sits below the sector average. If convertible bonds convert into shares or rights offerings are executed, the share count would rise and per-share measures would change, which matters when reading current multiples.

Compared with its past trading band, the recent price-to-book ratio sits near the lower end. These level comparisons describe where current multiples stand rather than judge value.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Narrowing operating losses

The operating loss narrowed to KRW 4.28 billion in 2025 from KRW 6.05 billion in 2024. The third-quarter 2026 operating loss was KRW 85.3 million, down from KRW 865 million a year earlier. Revenue in 2025 was KRW 76.2 billion, well above KRW 45.3 billion in 2022.

Distribution channels and diversification

Distribution of Logitech PC peripherals and Ecovacs home appliances through channels such as Coupang Rocket Delivery forms the core of revenue. The March 2026 articles of incorporation changes broadened business purposes to include advertising agency, live commerce and MCN work. The move into content and marketing is now reflected in filings.

Approved diagnostic kit on sale

The QPLEX Alz Plus dementia early diagnostic kit holds MFDS product approval and is on sale. The life care unit holds five bio pipelines covering inflammation, dementia and non-opioid pain relief. An approved product is an asset closer to commercialization than the rest of the pipeline.

09

Bear factors

Persistent losses and accumulated deficits

Operating losses have run for four consecutive years from 2022 to 2025. Losses have continued for five consecutive quarters from the third quarter of 2025 to the third quarter of 2026, and the last four quarters total KRW 9.03 billion in net loss attributable to controlling shareholders. The 2024 net loss attributable to controlling shareholders was KRW 80.4 billion.

Weaker financial structure and cash flow

The debt ratio rose from 51.2% in 2023 to 369.8% in 2025. Total liabilities of KRW 56.6 billion at the end of 2025 exceed total equity of KRW 15.3 billion. Operating cash outflow widened from KRW 2.14 billion in 2023 to KRW 8.29 billion in 2025.

Repeated financing disclosures and dilution

According to a Daily Yonhap report, cumulative convertible bond issuance decisions total KRW 70.5 billion, with a single-tranche potential dilution of 44.69%. Rights offering decisions, corrections and withdrawals were repeated between June and November 2026.

In March 2026, a designation as an unfaithful disclosure company was flagged over changes to rights offering terms.

10

Risk factors

Financial and liquidity risk

Operating cash outflows have continued and reached KRW 8.29 billion in 2025. A debt ratio of 369.8% and total liabilities of KRW 56.6 billion could mean repayment and refinancing pressure. Limited access to funding would restrict investment capacity.

Dilution and disclosure risk

If cumulative convertible bond issuance decisions of KRW 70.5 billion are executed, the share count could rise sharply. Repeated rights offering decisions, corrections and withdrawals point to uncertainty in the financing plan. The March 2026 designation notice shows that disclosure-related sanctions are also a live risk.

Concentration and bio development risk

Commerce revenue depends on the Logitech brand distribution and on platforms such as Coupang. Research and development costs in the bio unit are fixed and can add to earnings volatility. Clinical-stage pipelines can be delayed depending on trial results and approval timing.

11

What to watch next

  1. Ongoing from late November 2026

    Whether convertible bonds are converted and rights offerings are executed, and changes in the number of shares issued. Execution size will change per-share measures and the capital structure.

  2. End of March 2027 (statutory filing deadline)

    Confirmation of 2026 annual revenue, operating loss, operating cash flow, debt ratio and the non-operating breakdown in the annual report. The operating margin in that report is the key checkpoint.

  3. May 15, 2027 (statutory filing deadline)

    Whether the operating loss in the first-quarter 2027 report holds near the third-quarter 2026 level and whether the string of quarterly losses continues.

  4. Ongoing from late November 2026

    Sales of the QPLEX Alz Plus kit and clinical or approval disclosures for the bio pipeline. These show the timing of drug commercialization and whether the diagnostic kit contributes meaningfully to revenue.

12

Overall view

Hyper's revenue has risen for three consecutive years through 2025 to KRW 76.2 billion, and its operating loss narrowed to KRW 4.28 billion in 2025 from KRW 6.05 billion in 2024.

The third-quarter 2026 operating loss of KRW 85.3 million was the smallest of the last five quarters, but five consecutive quarters of losses and KRW 9.03 billion in net loss attributable to controlling shareholders over the last four quarters mean a shift to sustained profit has not yet been confirmed.

On the financial side, the debt ratio rose to 369.8% and operating cash outflow widened to KRW 8.29 billion in 2025. On funding, cumulative convertible bond issuance decisions of KRW 70.5 billion and repeated rights offering disclosures remain variables for dilution and financing.

On the business side, Logitech PC peripheral distribution, home appliance distribution, the broader business purposes covering advertising and live commerce, and the MFDS-approved diagnostic kit are cited as strengths.

The commercialization timing and revenue contribution of the drug pipeline are not confirmed by filings. The next checkpoints are whether the conversions and rights offerings are executed, the operating margin in the 2026 annual report, and the operating loss trend in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. valueline.co.kr
  2. thevc.kr
  3. comp.fnguide.com
  4. investing.com
  5. edaily.co.kr
  6. digitaltoday.co.kr
  7. edaily.co.kr
  8. kpinfo.kr
  9. job-post.co.kr
  10. m.news.nate.com
  11. dailyan.com
  12. orgo.kr
  13. judal.co.kr
  14. judal.co.kr

Report written 2026-11-15 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis